Niflumic acid (Standard)

Niflumic acid (Standard) is the analytical standard of Niflumic acid. This product is intended for research and analytical applications. Niflumic acid is a calcium-activated chloride channel blocker and COX-2 inhibitor with the IC50 value of 100 nM. Niflumic acid induces apoptosis through caspase-8/Bid/Bax pathway in lung cancer cells. Niflumic acide exhibits anti-tumor activity by affecting the expression of ERK1/2 and the activity of MMP2 and MMP9. Niflumic acid has orally bioactivity. Niflumic acid acts on rheumatoid arthritis[1][2][3][4][5][6][7][8].

Product Specifications

CAS Number

[4394-00-7]

UNSPSC

12352005

Hazard Statement

H301, H413

Target

Chloride Channel; COX; Reference Standards

Type

Reference Standards

Related Pathways

Immunology/Inflammation; Membrane Transporter/Ion Channel; Others

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/niflumic-acid-standard.html

Purity

99.93

Smiles

O=C(C1=CC=CN=C1NC2=CC=CC(C(F)(F)F)=C2)O

Molecular Formula

C13H9F3N2O2

Molecular Weight

282.22

Precautions

H301, H413

References & Citations

[1]Criddle, D.N., et al., Inhibitory action of niflumic acid on noradrenaline- and 5-hydroxytryptamine-induced pressor responses in the isolated mesenteric vascular bed of the rat. Br J Pharmacol, 1997. 120 (5) : p. 813-8.|[2]Jabeen, T., et al., Non-steroidal anti-inflammatory drugs as potent inhibitors of phospholipase A2: structure of the complex of phospholipase A2 with niflumic acid at 2.5 Angstroms resolution. Acta Crystallogr D Biol Crystallogr, 2005. 61 (Pt 12) : p. 1579-86.|[3]Picollo, A., et al., Mechanism of interaction of niflumic acid with heterologously expressed kidney CLC-K chloride channels. J Membr Biol, 2007. 216 (2-3) : p. 73-82.|[4]Yuliya V Kucherenko, et al. Niflumic Acid Affects Store-Operated Ca2+-Permeable (SOC) and Ca2+-Dependent K+ and Cl2 Ion Channels and Induces Apoptosis in K562 Cells. J Membr Biol. 2014 Jul;247 (7) :627-38.|[5]Byeong Mo Kim, et al. Combined treatment with the Cox-2 inhibitor niflumic acid and PPARc ligand ciglitazone induces ER stress/caspase-8-mediated apoptosis in human lung cancer cells. Cancer Lett. 2011 Jan 28;300 (2) :134-44.|[6]Shengqun Luo , et al. Niflumic acid exhibits anti-tumor activity in nasopharyngeal carcinoma cells through affecting the expression of ERK1/2 and the activity of MMP2 and MMP9. Int J Clin Exp Pathol|[7]I Florentin , et al. MODULATION OF IMMUNE RESPONSES IN MICE BY ORAL ADMINISTRATION OF NIFLUMIC ACID. Int J Immunopharmacol. 1989;11 (2) :173-83.|[8]Mitsuko Kondo , et al. Niflumic Acid Inhibits Goblet Cell Degranulation in a Guinea Pig Asthma Model. Allergol Int. 2012 Mar;61 (1) :133-42.